The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition:wherein: V is N or CR3 X is N or CR4 Y is N or CR5 Z is N or CR6 B is —(C═O)R1, a 5- to 10-membered heteroaryl group, or a group -L′″-NRR′, wherein R and R′ are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group R1 is a 5- to 10-membered heterocyclyl group, or —OR′, wherein R′ is a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group, or R1 is a proteinogenic α amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the α amino group, which amino acid is optionally esterified at the α carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group, or R1 is —NR″R′″, —NRIV-L′″-CONR″R′″, or —NRIV-L′″-COOR, wherein R, R″, R′″ and RIV are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group either (a) W is N and R9 and R2 together form a bond, or (b) W is CR8, R8 and R9 together form a bond and R2 is a hydrogen atom, or a C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocyclyl, -L′-A2, C3-C10 cycloalkyl, or —COOR′ group, wherein R′ is a hydrogen atom or C1-C6 alkyl group, or, when Z is a moiety CR6, R2 may form, together with R6 and the carbon and nitrogen atoms which connect R2 and R6 in the formula (I), a 5- to 6-membered heterocyclic ring R3 is a hydrogen atom, a halogen atom, or a hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, nitro, or —NR′R″ group, wherein R′ and R″ are the same or different and each represent a hydrogen atom or C1-C6 alkyl group R4 and R5 are the same or differe